The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Support side: Insider open-market buy — insiders or holders bought while this setup is live; see the timeline.
Radar 83 (high attention) · dilution pressure high · listing risk elevated · governance risk low · runway 6.8 mo · strongest signal: Offering (424B) (Jul 22, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway 6–12 months) coexists with live selling machinery (atm program, pipe, registered direct, offering (424b)). Base case is a discounted raise; the question is when, not if.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Jul 23, 2026 | ▲ Insider open-market buy | 1 open-market buys by 1 insider(s) (~$100,000) in 30d: Matheis Dennis 14,[email protected] 2026-07-23 filing | 28 |
| Jul 22, 2026 | ▼ Offering (424B) | 424B5 prospectus supplement 2026-07-22; 1 prior 424B filings in 12m filing | 48 |
| Jul 22, 2026 | ▼ ATM program | “atm” language in 8-K (EX-99.1) filed 2026-07-22 filing | 41 |
| Jul 22, 2026 | ▼ ATM program | “atm” language in 424B5 (424B5) filed 2026-07-22 filing | 38 |
| Jul 22, 2026 | ▼ Registered direct | “rdo” language in 8-K (EX-99.1) filed 2026-07-22 filing | 36 |
| Jul 22, 2026 | ▼ Registered direct | “rdo” language in 424B5 (424B5) filed 2026-07-22 filing | 34 |
| Jul 22, 2026 | ▼ PIPE | “pipe” language in 8-K (8-K) filed 2026-07-22 filing | 33 |
| Jul 22, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.1) filed 2026-07-22 filing | 32 |
| Jul 22, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-10.2) filed 2026-07-22 filing | 32 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 7,312,398 (2026-05-12) -> 9,799,481 (2026-08-11), +34% filing | 34 |
| Jun 30, 2026 | ▼ Runway 6–12 months | ~6.8 months runway: liquidity $13,961,000 (cash $6,634,000 + investments $7,327,000) as of 2026-06-30, burn $24,552,333/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 26 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →